Combination effect naringin and pravastatin in lipid profile and glucose in obese rats
| Autor: | Abdel K. Raffoul-Orozco, Ana E. Ávila-González, Christian M. Rodríguez-Razón, Trinidad García-Iglesias, Edsaul Emilio Perez-Guerrero, Edy David Rubio-Arellano, Teresa Arcelia Garcia-Cobian |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
Blood Glucose Male medicine.medical_specialty General Biochemistry Genetics and Molecular Biology 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Internal medicine medicine Animals 030212 general & internal medicine Obesity General Pharmacology Toxicology and Pharmaceutics Rats Wistar Naringin Triglycerides Pravastatin medicine.diagnostic_test Cholesterol HDL Lipid metabolism General Medicine medicine.disease Lipid Metabolism Lipids Rats 030104 developmental biology Endocrinology Glucose chemistry Murine model Flavanones Drug Therapy Combination medicine.symptom Lipid profile Weight gain Dyslipidemia medicine.drug |
| Zdroj: | Life sciences. 193 |
| ISSN: | 1879-0631 |
| Popis: | The purpose of this study was to compare the effect of naringin 100mg/kg in combination with pravastatin 10mg/kg by gavage for 6weeks compared with monotherapy over lipid profiles, glucose levels and weight in murine model of obesity.The study design was planned with 5 groups of 6 male Wistar Albina rats: Group 1: control with balanced food and vehicle (C-); Group 2: control with Obesity and vehicle (C+); Group 3: Obesity+naringin (N); Group 4: Obesity+pravastatin (P); Group 5: Obesity+pravastatin+naringin (NP). Obesity was developed with a food model.The naringin groups showed a decrease in weight gain and low glucose values compared to the control group (weight NP:311.4 vs C+:348.6; glucose NP: 173.12 vs C+:235.56) (p0.05); the group with naringin+pravastatin combination showed the total cholesterol (TC), LDL and triglycerides (TGs) to normal levels (TC NP:51.6 vs C+:83.4; LDL NP:9.32 vs C+:32.32; TGs NP:39.4 vs C+:89.4) (p0.05); but was not statistically significant compared with monotherapy.The combination of naringin and pravastatin did not appear to be better than monotherapy on lipids, but its use could generate euglycemic and antiobesogenic effects, in addition to diminishing the adverse hepatic effects of pravastatin in rats. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect